PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF THE EYE

Abstract: A pharmaceutical composition for the treatment of disorders of the anterior segment of the eye or for the preservation of isolated cornea. The composition comprises, as an active ingredient, an agent capable of causing a net efflux of cholesterol from cells.

Description: PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF THE EYE FIELD OF THE INVENTION The present invention concerns pharmaceutical compositions for the treatment of the eyes and more specifically for the treatment of disorders of the anterior segment of the eye. BACKGROUND OF THE INVENTION The protective structures of the anterior surface of the eye include the eyelids, conjunctiva, and the cornea. The posterior surfaces of the lids are covered with a mucous membrane and the palpebral conjunctiva which reflects onto the eye to become the bulbar conjunctiva. The bulbar conjunctival epithelium is continuous with the corneal epithelium which accounts for about 10% of the anterior surface of the eye and is where most of the stationary refraction occurs. The corneal epithelium is 4-5 cells thick and the superficial cells contain many microvilli. These aid in maintaining the moisture of the epithelial surface by promoting the adhesion of the tear film to the surface. This film lubricates the anterior surface of the eye to decrease the frictional forces arising from the persistent blinking movements of the eyelids, foreign particles on the surface of the eye, and the rotational movements of the eyeball. The tear film also transfers oxygen from ambient air to the cornea. The anterior surface of the eye is vulnerable to damages inflicted by various causes including mechanical abrasion of the cornea; contact lens wearing; spontaneous peeling of the epithelium; damaged epithelium and stroma following photo-refractive keratectomy; chemical burns; over exposure to ultraviolet light including sunlight; systemic diseases such as Sjogren syndrome, Steven- Johnson syndrome, Cicatricial pemphigoid syndrome; chronic edema of cornea with recurrent erosion of epithelium; impaired tear film formation, and conditions following damage of epithelia due to radial keratotomy. Aging often causes disorders resulting from slow regeneration of the epithelium. The impaired regeneration and abnormality of the cells causes thinning of the epithelial layer and its impaired adherence to the basal lamina thus decreasing the ability of the cornea to retain the tear film leading to further epithelial damage. Following injury to the corneal epithelium, nearby cells retract slightly, round up and begin an ameboid migration from the basal layer across the exposed basement membrane to cover the defect with a new monolayer of cells. These cells then take on the characteristics of a new basal layer and undergo mitosis to gradually fill in the defect with the full complement of four to five layers of cells. Present treatment for corneal wounds involves applying eye drops to the surface in order to protect the delicate healing process from erosion due to blinking and the other sources of friction. There are no currently used medicaments that promote the healing process itself. Attempts to administer fibronectin in order to promote healing of persistent defects of the corneal epithelium failed (Fukuda et al, Am J. Ophthalmol., 119(3):281-287, (1995)). It would have been highly desirable to provide an ophthalmic composition capable of protecting the corneal epithelium and enhancing its healing and regeneration. The rate of cell proliferation in many cell types has been correlated with the rate of cholesterol synthesis, and more specifically with the biosynthesis of various intermediates in the cholesterol biosynthesis pathway and their by-products such as farnesylated proteins and others. Thus, inhibition of an early enzyme in the biosynthesis of cholesterol inhibits cell growth in cultured fibroblasts (McGuire et al, J. Biol. Chem., 268:22227-22230, (1993)). Factors which cause cholesterol efflux from cells (e.g. high density lipoproteins, HDL) alleviate the negative feedback inhibition of cholesterol synthesis and enhance growth of MDCK cells in vitro (Gospodarowicz et al., J. Cell. PhysioL, 117:76-90, (1983)). The cornea is an avascular organ obtaining nutrition from the vasculature of the limbus by diffusion. At the outer surface of the cornea, the epithelium is essentially isolated from the plasma's large complexes such as HDL which hardly diffuse through the cornea. Thus, HDL which performs the "reverse cholesterol transport" from peripheral organs to the liver (Glomset, J.A., J. Lipid Res., 9:155-167, 1968) is unable to perform this task in the corneal epithelium. SUMMARY OF THE INVENTION The present invention is based on the surprising finding that high density lipoprotein (HDL), or a combination of its non-cholesterol lipid constituents (phospholipids, and other lipids such as triglycerides and glycerol), which are capable of forming reconstituted HDL, promotes normal healing and regeneration of damaged eye epithelium. Both HDL and said lipid constituents were able to initiate the process of healing, to increase its rate, and to promote reversion of the damaged epithelium of the eye to the normal state, i.e. where the damaged area is covered again by layers of epithelial cells. Thus, the present invention concerns a pharmaceutical composition for the treatment of disorders of the anterior segment of the eye comprising, as an active ingredient, at least one agent capable of causing a net efflux of cholesterol from cells, together with an opthalgestically acceptable carrier. The term "treatment" refers to curing of the disorder of the eye, to alleviation of some of the undesired symptomes of various eye disorders, and/or to prevention of various eye disorders before they are manifested. The term "anterior segment of the eye" refers to the corneal and conjunctival epithelium and includes the epithelial cells, as well as the glands present in the epithelium. The term "disorders of the anterior segment of the eye" refers to disorders which cause physical damage to the corneal or conjunctival epithelium, to disorders which decrease the rate of regeneration of cells making up this epithelium, or to disorders causing diminished secretions from glands present in the conjunctival epithelium, or to a combination of some of these disorders. Typical disorders of the anterior segment of the eye caused by physical or chemical damage are: mechanical abrasion of the cornea, corneal epithelial defects created by wearing contact lenses, corneal epithelial defects created by spontaneous peeling of the epithelium, corneal damage following photo-reactive keratectomy, injuries caused by chemical substances, damage caused by exposure to ultraviolet light, systemic diseases creating damage to the corneal epithelium and conjunctiva, for example, Sjorgren- Syndrome, Steven- Johnson Syndrome, Cicatricial Pemphigoid Syndrome, chronic edema of the cornea with recurrent erosion of epithelium and the like. Typical disorders of the anterior segment of the eye caused by a decrease in the rate of generation of cells include deterioration of the eye due to old age or an anti-proliferative treatment. Typical disorders of the anterior segment of the eye caused by diminished secretion are dry eye and tear film dysfunction due to old age, various diseases or as side effects of systemic medication. The pharmaceutical composition of the present invention may be administered to persons suffering from disorders which cause damage to the corneal or conjunctival epithelia, or in conjunction with treatments which are known to cause such damage, for example, laser or radial keratectomy or administration of various systemic or topical medications. The pharmaceutical compounds of the invention, due to their amphoteric nature, are also capable of substituting for the natural tear film and may serve as lubricants, and thus, beyond their effect in the promotion of healing of the damaged eye epithelium, are also capable of relieving the symptoms of dry eye. Dry eye symptomes may be the cause of the physical damage of the epithelium or the result of it, or may be the sole disorder affecting the person's eye. Where the pharmaceutical composition is intended, inter alia, to treat dry eye, it should also include water/saline and a viscous substance such as an ophthalmologically acceptable polysaccharide in order to mimic as closely as possible the constituants of natural tears. The active agents of the invention are those capable of causing a net efflux of cholesterol from cells. Locating candidate agents capable of generating a net cholesterol efflux, may be carried out, for example, by determining the net efflux of labeled cholesterol from cells according to the method described in Naphtali Savion and Shlomo Kotev-Emeth, Eur. J. Biochem., 183:363-370 (1989). Briefly, confluent endothelial or smooth muscle cultures are allowed to incorporate H -cholesterol. The candidate to be tested as an effector of cholesterol efflux is then added to the cell culture and the percentage of radioactivity remaining in the cells after 24 firs, is determined. Candidates which are able to significantly lower the amount of labeled cholesterol in these cells, are those which are capable of serving as active agents in the pharmaceutical compositions of the invention. Preferably, the present invention concerns a pharmaceutical composition for the treatment of disorders of the anterior segment of the eye comprising as an active agent at least one compound selected from the group consisting of: i. high density lipoprotein (HDL); ii. phospholipids and/or spingolipids; iii. a composition of matter comprising phospholipids and at least one other lipid component of HDL other than cholesterol and cholesteryl-ester; and iv. at least one HDL Apolipoprotein. The term "high density lipoprotein" refers to lipoproteins which may be isolated from humans or other mammalian sources (e.g. bovine plasma), for example, as specified in Denis Gospodarowicz "Methods for Preparation of Media, Supplements, and Substrata for Serum-Free Animal Cell Culture", pp. 69-86, 1984, Alan R. Liss, Inc., New York, New York or other isolation methods based on the density of the HDL. The term "phospholipids", refers to phospholipids which naturally occur in HDL such as phosphatidylcholine, phosphatidylserine and phosphatidylinositol. An example of "sphingo lipids" is sphingomyelin. The term "and at least one other lipid component of HDL other than cholesterol and cholesteryl-ester" refers to glycerides, glycerol and triglycerides. In accordance with the invention glycerides and triglycerides which are not present naturally in HDL, but have an analogous function to glycerides and triglycerides present in HDL may also be used. The composition of matter comprising the non-cholesterol and the non-cholesteryl-ester lipid components of HDL (generally phospholipids, triglycerides and glycerides) is termed "reconstituted HDL" (Gillote et al, J. Biol. Chem., 271:23792-23798, 1996). This term refers to a complex comprising phospholipids, triglycerides and glycerides, which differs from natural HDL by the absence of cholesterol, cholesteryl-esters, and apolipoproteins. Reconstituted HDL particles are prepared by the chelate dispersion/Bio-Bead removal technique (Sparks et al, J. Biol. Chem. 267:25830-25838, 1992). Typically, compounds which are used in intravenous nutrition as a source of essential fatty acids, are suitable for serving as the lipid components of HDL. Example being Intralipid , (Pharmacia AB, Sweden), Lipofundin (Braun Melsungen AG, Germany) and others. The term "HDL apolipoproteins" refers typically to apolipoprotein A-I, A-IN and E-apolipo-proteins or a combination thereof, either isolated from a human or mammalian source (Savion and Gamliel, Arteriosclerosis, 8:178-186, 1988). Apolipoprotein-E is purified according to Wemette-Hammond et al, J. Biol. Chem., 264:9094-9101, 1989. The HDL apolipoproteins may also be prepared by various genetic engineering methods described in Breslow, et al, Proc. Natl. Acad. Sci, 79:6861-6865, 1982. For example: Human Apolipoprotein A-I gene can be prepared according to the method of Karathanasis et al, Proc. Natl. Acad. Sci, 80:6147-6151, 1983; Human Apolipoprotein A-IV gene according to Elshourbagy, et al, J. Biol. Chem., 262:7973-7981, 1987; and Human Apolipoprotein E gene according to Das, et al, J. Biol. Chem., 260: 6240-6247, 1985; Paik, et al, Proc. Natl. Acad. Sci, 82.3445-3449, 1985. The composition of the present invention may further comprise albumin. Albumin is the most abundant plasma protein and serves as the plasma carrier of free fatty acids. Each albumin molecule has 27 binding sites for fatty acids. Albumin may thus serve as a scavenger for toxic free fatty acids released by damaged anterior chamber tissue included in reconstituted HDL. The pharmaceutical compositions of the invention may further comprise other ingredients having ophthalgesic affects, especially those which are known to facilitate healing and regeneration of cornea and conjunctiva such as growth factors, for example, keratinocyte growth factor (KGF/FGF7), or epidermal growth factor (EGF) and other growth factors of the EGF family known in the art; various attachment factors such as laminin or fibronectin, and extracellular matrix components such as collagen, heparan sulfate proteoglycans and others. The pharmaceutical compositions of the invention may also include agents capable of providing ultraviolet light protection, such as oxybenzone 3%, and other such preparations known in the art. The pharmaceutical compositions of the invention should be administered in the form of eye drops or eye salves together with opthalgestically acceptable carriers. The composition may be in the form of an emulsion, micelles liposomes, etc. The concentration of the active ingredients in the composition should be in the range of 0.1-20%, preferably 0.2-10%, most preferably 0.2-2%. Some disorders of the eye that are to be treated by the pharmaceutical compositions of the invention include diminished liquid clearance from the eye causing water retention which eventually leads to the rupture of the eye membranes. In such cases, it is preferable that the compositions of the invention be presented in a hyperosmotic formulation which can serve to draw excess liquid from the eye. Such hyperosmotic formulation may be formed, for example, by the addition of NaCl to the composition. By another aspect, the invention comprises a method for the treatment of disorders of the anterior segment of the eye comprising administering to a subject in need of such treatment at least one agent capable of causing a net efflux of cholesterol from cells. By another aspect, the invention comprises use of at least one agent capable of causing a net efflux of cholesterol from cells for the preparation of a medicament for the treatment of disorders of the anterior segment of the eye. By yet another aspect, the present invention concerns a storage preparation for storing and maintaining isolated corneas, for example, in an eye bank. In order to maintain the viability of epithelial cells as well as the exposed endothelium of the eye, it is preferable to add to the storage medium an effective amount of at least one agent capable of causing a net efflux of cholesterol from cells, as explained above. The invention now will be illustrated with reference to some non-limiting drawings and examples. BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 shows fluorescein staining of untreated damaged eye cornea 5 days after surgery (x 16); Fig. 2 shows fluorescein staining of untreated damaged eye cornea 12 days after surgery (x 16); Fig. 3 A shows the histological appearance of normal cornea; Fig. 3B shows the histological appearance of untreated damaged eye cornea 12 days after surgery; Fig. 4 shows fluorescein staining of damaged eye cornea following Intralipid treatment; Fig. 5 shows the histological appearance of damaged eye cornea following Lyteers treatment; Fig. 6 shows fluorescein staining of damaged eye cornea after 3 days of treatment with HDL; Fig. 7 shows fluorescein staining of damaged eye cornea at the end of treatment with HDL; Fig. 8 shows the the histological appearance of damaged eye cornea after HDL treatment; Fig. 9 shows the histological appearance of damaged eye cornea following 7 days of treatment with Lipofundin™; and Fig. 10 shows the histological appearance of damaged eye cornea following 7 days of treatment with Lyeteers™. DET AILED DESCRIPTION OF THE INVENTION I. Experimental Procedures A. Animal model of comeal epithelium and conjunctival epithelium damage A rabbit model for keratoconjunctivitis (Gilbard et al, J. Inv. Ophthal. Vis. Sci, 2:225-228 (1987)) was used with slight modification. Surgery performed on anesthetized rabbits using a surgical microscope (Inami, Japan) involved excision of the plical fold over the eye, occlusion of the lacrimal duct, and peeling of the palpebral and bulbar conjunctiva. This surgery was done on one eye of 20 rabbits of average age 3 months of both sexes. Surgery and all subsequent treatments were done in accordance with ARVO rules for animal care in research. Tear film osmolarity is elevated by postoperative day 1. Corneal epithelial glycogen levels decline progressively, and conjunctival goblet cell density decreases. These pathologies lead to comeal epithelium damage covering the entire comeal surface by the fifth postoperative day, and it was at this time that treatment of the eyes commenced. B. HDL preparation HDL was prepared from human plasma by differential ultracen- trifugation flotation (Havel et al, "Distribution and chemical composition of ultracentrifugally lipoproteins in human serum", J. Clin. Invest., 34:1345-53, (1995)). C. Evaluation of Rabbit Cornea Lesions in fluorescein stained corneas were clinically evaluated by biomicroscopy using a slit lamp (Haag Streit, Switzerland) with cobalt filter illumination. Photography of the fluorescein staining was taken with a slit lamp mounted camera (Topcon, Japan). At the end of each experiment, the rabbits were sacrificed and the cornea were excised, fixed in paraformaldehyde and examined for epithelial lesions. D. Histological examination At the end of the treatment, the rabbits were sacrificed by a lethal dose of intravenously injected pentobarbitone. The eyes were enuclated and the corneas fixed in 4% paraformaldehyde. Corneas were embedded in paraffin blocks, sectioned, and with hematoxylin-eosine for light microscope examination. II. Treatment of corneal epithelium damage caused by conjunctival epithelium damage Example 1 Rabbits with cornea damage induced as above were treated as follows: Five rabbits were treated with commercially available artificial tears (Lyteers ™ ), five rabbits were treated with HDL (lmg protein/ml) in phosphate buffered saline, five rabbits were treated with a commercially available lipid mixture (10% Intralipid ™ : 10% soybean oil, 1.2% egg phospholipids, 2.2% glycerol), and two rabbits were left untreated. Treatment consisted of applying two drops to the eye 3 times a day for seven consecutive days. The eyes were evaluated clinically during the experiment and pictures were taken every other day of the fluorescein stained corneas. Fluorescein staining of damaged eyes 5 and 12 days following surgery is shown in Figs. 1 and 2, respectively. As can be seen, the surface of the untreated eye became progressively more scratched and opaque with time leading eventually to blurred vision. Histological staining of damaged eye is shown in Fig. 3B and is compared to histological staining of normal eye 3A. As can be seen, in the damaged eye there has been complete erosion of the exposed epithelium due to persisant rubbing of the epithelium by the lids as well as severe keratitis and vascularization of the cornea. Animal eyes that were treated with Intralipid show complete reversal to normal morphological structure as indicated by fluorescein staining (Fig. 4). However, animal eyes treated with Lyteer , (Fig. 5) (commercially available artifical tears composed mainly of water and a viscous substance) did not return to normal. In contrast to normal eyes, the damaged area did not become covered again with normal layers of cuboidal epithelial cells and a single top layer of wing cells, but was covered instead by only a single layer of wing cells. These results indicate that artificial tears such as Lyteer cannot promote regeneration of normal eye epithelium. In contrast to this, animal eyes treated with HDL showed essentially a complete return to normal morphological structure as indicated by fluorescein staining taken on the third day (Fig. 6) and at the end of treatment (Fig. 7) as well as by histological staining (Fig. 8). Histological staining shows essentially a complete return to normal of the eye epithelium characterized by formation of several layers of cuboidal cells and a single top layer of wing cells. These results clearly indicate that both HDL and Intralipid are able to promote healing and regeneration of damaged eye epithelium and return to normal epithelium. Example 2 Three rabbits underwent central comeal peeling of the epithelium in both eyes. The area of peeling, 8 mm in diameter, was first demarcated with trephine, and the epithelium excised with a scalpel. The right eye of each rabbit was treated with two drops of Lipofundin™ 10% three times a day, while the left eye was treated with the same dose of Lyeteers™. The cornea were stained with fluorescein and photographed immediately after epithelium removal and on the third and fifth day afterwards. On the seventh day, the rabbits were sacrificed by a lethal dose of pental and the corneas were excised, fixed and stained for light microscopy. The denuded area in the fluorescein and fixed corneas was determined, and the extent of remaining damage calculated as the remaining denuded area divided by the initial denuded area. The results appear in Table 1 below which gives the fraction of initial damage remaining 0, 3, 5, and 7 days after peeling the epithelium. The results show that the rate of healing was faster in the Lipofundin™ treated eyes. Figs. 9 and 10 show the epithelium of a Lipofundin™ treated eye and a treated eye, respectively, after 7 days of treatment. Whereas the Lipofundin™ appears close to, in the Lyeteers™ treated eye the epithelium still appears thin, immature, and containing only flat and wing cells which have migrated to the denuded area. Table 1 III. Clinical study on the effect of Lipofundin™ on dry eye Experimental Eight female patients suffering from dry eye and presenting less than 10 mm of wet strip in a Shirmer test, were included in this study. The patients ranged in age from 62 to 74 years. Each patient received a bottle of Lipofundin™ 5% and was instructed to instill two drops in one eye three times a day for one week, while continuing the previous treatment in the other eye. Each patient was asked to fill out a questionnaire before and after the week of treatment in which she was to rank the following parameters on a scale of 0 (no complaint) to 4 (very severe): itching, tearing, a sensation of "sand" under the upper eyelid, and photophobia. The appearance of the anterior segments of the eyes was evaluated clinically for redness, inflammation, and discharge from the conjunctival sac. Results The results of the clinical studies are given in Table 2. All of the patients reported a general improvement in their symptoms and asked to continue treatment with Lipofundin™ for a longer period of time. Seven of the eight patients had no complaints about the treatment. One patient, presenting the most severe case of dry eye at the beginning of the study, complained of a burning sensation lasting about two minutes following the instillation of Lipofundin™ during the first two days of treatment. Lipofundin™ was thus well tolerated by the patients and ameliorates symptoms in people suffering form dry eye. Table 2

Claims: CLAIMS: 1. A pharmaceutical composition for the treatment of disorders of the anterior segment of the eye comprising, as an active ingredient, at least one agent capable of causing a net efflux of cholesterol from cells, together with an ophthagestically acceptable carrier. 2. A pharmaceutical composition according to Claim 1, wherein the anterior segment of the eye is the comeal epithelium, stromal conjunctiva, and the glands present in both. 3. A pharmaceutical composition according to Claim 1, wherein the disorders are manifested by physical and chemical damage to the conjunctival and comeal epithelia. 4. A pharmaceutical composition according to Claim 3, wherein the disorders are selected from the group consisting of: mechanical abrasion of the comea; comeal epithelial defects created by contact lens wearing; comeal epithelial defects created by spontaneous peeling of the epithelium; comeal damage following photo-refractive keratectomy; injuries caused by chemical substances; injuries caused by ultraviolet light exposure; systemic diseases causing damage to the comeal epithelium and conjunctiva; chronic edema of comea with recurrent erosion of epithelium; and conditions following damage of epithelia due to radial keratotomy. 5. A pharmaceutical composition according to Claim 1, wherein the disorders include a decrease in secretion from glands located in the conjunctiva. 6. A pharmaceutical composition according to Claim 5, wherein the disorders are selected from the group consisting of: dry eye and tear film disfunction caused by medication. 7. A pharmaceutical composition according to Claim 1, wherein the disorders are manifested by a slow rate of regeneration of cells of the anterior segment of the eye. 8. A pharmaceutical composition according to Claim 7, wherein the slow rate of regeneration is caused by old age, or by administration of anti-proliferative substances. 9. A pharmaceutical composition according to Claims 1 to 8, wherein said agent is one or more of the group consisting of: i. high density lipoprotein (HDL); ii. phospholipids and/or sphingolipids; iii. a composition of matter comprising phospholipids and at least one other lipid component of FIDL other than cholesterol and cholestryl-ester; and iv. at least one HDL Apolipoprotein. 10. A pharmaceutical composition according to Claims 1 to 8 wherein said agent is Lipofundin™ 11. A pharmaceutical composition according to Claims 1 to 8 wherein said agent is Intralipid™ 12. A pharmaceutical composition according to Claims 9-11, further comprising albumin. 13. A pharmaceutical composition according to Claim 9, wherein the HDL is human or bovine HDL. 14. A pharmaceutical composition according to Claim 9, wherein the phospholipids are selected from the group consisting of: phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinosital. 15. A pharmaceutical composition according to Claim 9, wherein the sphingolipids are sphingomyelins. 16. A pharmaceutical composition according to Claim 9, wherein the other lipid components of HDL are triglycerides and/or glycerol. 17. A pharmaceutical composition according to Claim 9, wherein the apolipoprotein is selected from the group consisting of: Apolipoprotein A-I, Apolipoprotein A-IV and Apolipoprotein E or a combination of one or more apolipoproteins. 18. A pharmaceutical composition according to Claims 1 to 17, further comprising a growth factor, an attachment factor or an extracellular component. 19. A pharmaceutical composition according to Claim 18, wherein the growth factor is selected from the group consisting of: Keratinocyte Growth Factor (KGF/FGF7), Epidermal Growth Factor (EGF) and other growth factors of the FGF family. 20. A pharmaceutical composition according to Claim 18, wherein the attachment factor is selected from the group consisting of: laminin and fibronectin. 21. A pharmaceutical composition according to Claim 18, wherein the extracellular matrix components are selected from the group consisting of: collagen and heparan sulfate proteoglycans. 22. A pharmaceutical composition according to any one of Claims 1 to 21 further comprising an agent capable of providing protection from UN. radiation. 23. A pharmaceutical composition according to Claim 22, wherein the agent capable of providing protection from U.V. radiation is oxybenzone. 24. A method for the treatment of disorders of the anterior segment of the eye comprising administering to a subject in need of such treatment at least one agent capable of causing a net efflux of cholesterol from cells. 25. A method according to Claim 24, wherein the anterior segment of the eye is the comeal epithelium, stromal conjunctiva, and the glands present in both. 26. A method according to Claim 24, wherein the disorders are manifested by physical and chemical damage to the conjunctival and comeal epithelia. 27. A method according to Claim 26, wherein the disorders are selected from the group consisting of: mechanical abrasion of the comea; comeal epithelial defects created by contact lens wearing; comeal epithelial defects created by spontaneous peeling of the epithelium; comeal damage following photo-refractive keratectomy; injuries caused by chemical substances; injuries caused by ultraviolet light exposure; systemic diseases causing damage to the comeal epithelium and conjunctiva; chronic edema of comea with recurrent erosion of epithelium; and conditions following damage of epithelia due to radial keratotomy. 28. A method according to Claim 24, wherein the disorders include a decrease in secretion from glands located in the conjunctiva. 29. A method according to Claim 28, wherein the disorders are selected from the group consisting of: dry eye and tear film disfunction caused by medication. 30. A method according to Claim 24, wherein the disorders are manifested by a slow rate of regeneration of cells of the anterior segment of the eye. 31. A method according to Claim 30, wherein the slow rate of regeneration is caused by old age, or by administration of anti-proliferative substances. 32. A method according to Claims 24 to 31, wherein said agent is one or more of the group consisting of: i. high density lipoprotein (HDL); ii. phospholipids and/or sphingolipids; iii. a composition of matter comprising phospholipids and at least one other lipid component of HDL other than cholesterol and cholestryl-ester; and iv. at least one HDL Apolipoprotein. 33. A method according to Claims 24 to 31 wherein said agent is Lipofundin™ 34. A method according to Claims 24 to 31 wherein said agent is Intralipid™ 35. A method according to Claims 32-34, further comprising administering albumin. 36. A method according to Claim 32, wherein the HDL is human or bovine HDL. 37. A method according to Claim 32, wherein the phospholipids are selected from the group consisting of: phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinosital. 38. A method according to Claim 32, wherein the sphingolipids are sphingomyelins. 39. A method according to Claim 32, wherein the other lipid components of HDL are triglycerides and/or glycerol. 40. A method according to Claim 32, wherein the apolipoprotein is selected from the group consisting of: Apolipoprotein A-I, Apolipoprotein A-IV and Apolipoprotein E or a combination of one or more apolipoproteins. 41. A method according to Claims 24 to 40, further comprising a growth factor, an attachment factor or an extracellular component. 42. A method according to Claim 41, wherein the growth factor is selected from the group consisting of: Keratinocyte Growth Factor (KGF/FGF7), Epidermal Growth Factor (EGF) and other growth factors of the FGF family. 43. A method according to Claim 41, wherein the attachment factor is selected from the group consisting of: laminin and fibronectin. 44. A method according to Claim 41, wherein the extracellular matrix components are selected from the group consisting of: collagen and heparan sulfate proteoglycans. 45. A method according to any one of Claims 24 to 44 further comprising administering an agent capable of providing protection from U.V. radiation. 46. A method according to Claim 45, wherein the agent capable of providing protection from UN. radiation is oxybenzone. 47. Use of at least one agent capable of causing a net efflux of cholesterol from cells for the preparation of a medicament for the treatment of disorders of the anterior segment of the eye. 48. A use according to Claim 47, wherein the anterior segment of the eye is the corneal epithelium, stromal conjunctiva, and the glands present in both. 49. A use according to Claim 47, wherein the disorders are manifested by physical and chemical damage to the conjunctival and comeal epithelia. 50. A use according to Claim 49, wherein the disorders are selected from the group consisting of: mechanical abrasion of the comea; comeal epithelial defects created by contact lens wearing; comeal epithelial defects created by spontaneous peeling of the epithelium; comeal damage following photo-refractive keratectomy; injuries caused by chemical substances; injuries caused by ultraviolet light exposure; systemic diseases causing damage to the comeal epithelium and conjunctiva; chronic edema of comea with recurrent erosion of epithelium; and conditions following damage of epithelia due to radial keratotomy. 51. A use according to Claim 47, wherein the disorders include a decrease in secretion from glands located in the conjunctiva. 52. A use according to Claim 51, wherein the disorders are selected from the group consisting of: dry eye and tear film disfunction caused by medication. 53. A use according to Claim 47, wherein the disorders are manifested by a slow rate of regeneration of cells of the anterior segment of the eye. 54. A use according to Claim 53, wherein the slow rate of regeneration is caused by old age, or by administration of anti-proliferative substances. 55. A use according to Claims 47 to 54, wherein said agent is one or more of the group consisting of: i. high density lipoprotein (HDL); ii. phospholipids and/or sphingolipids; iii. a composition of matter comprising phospholipids and at least one other lipid component of HDL other than cholesterol and cholestryl-ester; and iv. at least one HDL Apolipoprotein. 56. A use according to Claims 47 to 54 wherein said agent is Lipofundin™ 57. A use according to Claims 47 to 54 wherein said agent is Intralipid™ 58. A use according to Claim 54, wherein the HDL is human or bovine HDL. 59. A use according to Claim 54, wherein the phospholipids are selected from the group consisting of: phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinosital. 60. A use according to Claim 54, wherein the sphingolipids are sphingomyelins. 61. A use according to Claim 54, wherein the other lipid components of HDL are triglycerides and/or glycerol. 62. A use according to Claim 54, wherein the apolipoprotein is selected from the group consisting of: Apolipoprotein A-I, Apolipoprotein A-IV and Apolipoprotein E or a combination of one or more apolipoproteins. 63. A storage medium for the preservation of isolated comea comprising at least one agent capable of causing net efflux of cholesterol from cells. 64. A storage medium according to Claim 63, wherein the agent capable of causing a net efflux of cholesterol from cells is one or more of the group consisting of: i. high density lipoprotein (HDL); ii. phospholipids and/or sphingolipids; iii. a composition of matter comprising phospholipids and at least one other lipid component of HDL other than cholesterol and cholestryl-ester; and iv. at least one HDL Apolipoprotein. 65. A storage medium according to Claim 63, wherein the agent capable of causing a net efflux of cholesterol from cells is one or more of the group consisting of: i. Lipofundin™ ii. Intralipid™ 66. A storage medium according to Claims 64 and 65, further comprising albumin. 67. A storage medium according to Claim 64, wherein the HDL is human or bovine HDL. 68. A storage medium according to Claim 64, wherein the phospho-lipids are selected from the group consisting of: phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine and phosphatidylinosital. 69. A storage medium according to Claim 64, wherein the sphingolipids are sphingomyelin. 70. A storage medium according to Claim 64, wherein the other lipid components of HDL are triglycerides and/or glycerol. 71. A storage medium according to Claim 64, wherein the apolipoprotein is selected from the group consisting of Apolipoprotein A-I, Apolipoprotein A-IV and Apolipoprotein E or a combination of one or more apolipoproteins.

Inventors: SAVION NAPHTALI, SOLOMON ARIEH, SAVION, NAPHTALI, SOLOMON, ARIEH
Applicants: SAVION NAPHTALI, SOLOMON ARIEH, UNIV RAMOT, RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH &, SAVION, NAPHTALI, SOLOMON, ARIEH
Application year: 1998
Main classification: A61K38
IPC codes: A61K38